Sumary of Combination antibody therapies retain potency against SARS-CoV-2 variants, FDA / HHS research:
- Researchers in the United States have conducted a study showing that while variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can compromise the effectiveness of single therapeutic antibodies at preventing severe coronavirus disease 2019 (COVID-19), many combination antibody products remain potent against the variants.
- However, several viral variants have emerged containing multiple mutations in the spike that confer resistance to these antibodies.
- To help predict this resistance, the researchers profiled the resistance patterns of 25 clinical-stage neutralizing antibodies (nAbs) against a large panel of variants containing single and multiple substitutions in the spike protein.
- However, most combination nAb products and polyclonal nAbs retained their potency against the variants.
- Carol Weiss and colleagues also found that the presence of critical substitutions in variants containing multiple spike substitutions were predictive of resistance.
- The researchers say the findings show that epistatic interactions in the spike protein can modify virus susceptibility to therapeutic antibodies, highlighting the importance of assessing antibody potency in the context of all substitutions present in a variant.
- More about antibody-based approaches to controlling the pandemic Since the COVID-19 outbreak first began in late 2019, intense efforts to control SARS-CoV-2 transmission and prevent severe disease have led to the development of antibody-based countermeasures, including vaccines, therapeutic monoclonal antibodies and convalescent plasma.
- Five nAb products that are in clinical use after having received emergency use authorization from the FDA target the SARS-CoV-2 spike protein.